Altruist Biologics Advances Localized Manufacturing for Multinational Client with NMPA Priority Review

Regulatory Progress in China

Altruist Biologics, a CDMO subsidiary of Innovent Biologics, has announced that China’s National Medical Products Administration (NMPA) has accepted a new drug application (NDA) for the domestic manufacturing of a biologic drug developed by a multinational pharmaceutical firm. The NMPA has also granted priority review for this application, a step expected to expedite the regulatory timeline for the product.

This development marks a significant transition for the client, moving from overseas production to local manufacturing in China. This initiative utilizes the NMPA's 2024 regulatory framework, which aims to facilitate localized manufacturing processes.

Operational Capabilities and Future Outlook

Altruist Biologics provides end-to-end CMC (Chemistry, Manufacturing, and Controls) support for its partners. Key aspects of their infrastructure include:

• Hangzhou Facility: Currently features 80,000 liters of operational capacity via four 20,000-liter bioreactors.
• Future Expansion: A 2,000-liter single-use production line is currently under construction, with operations expected to begin by mid-2027.
• Specialized Facilities: The site includes dedicated infrastructure for ADC and AXC bioconjugation, supporting both clinical and commercial scale needs.

Dr. Kaisong Zhou, CEO of Altruist Biologics, stated that the priority review status reflects collaborative efforts to strengthen supply chain resilience and expand patient access to innovative medicines in China. Interested parties can verify specific service capabilities and compliance records on the company's official website at www.altruistbio.com.